DAFNA Capital Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-612,975
| Closed | -$24.1M | – | 83 |
|
|
2023
Q2 | $24.1M | Hold |
612,975
| – | – | 6.59% | 2 |
|
|
2023
Q1 | $14.9M | Buy |
612,975
+7,000
| +1% | +$153K | 4.47% | 3 |
|
|
2022
Q4 | $13M | Buy |
605,975
+204,499
| +51% | +$4.36M | 3.65% | 6 |
|
|
2022
Q3 | $7.2M | Sell |
401,476
-1,000
| -0.2% | -$13.1K | 1.94% | 17 |
|
|
2022
Q2 | $3.87M | Buy |
402,476
+104,000
| +35% | +$1.31M | 1.06% | 31 |
|
|
2022
Q1 | $5.02M | Buy |
298,476
+22,500
| +8% | +$333K | 1.31% | 22 |
|
|
2021
Q4 | $4.61M | Buy |
275,976
+59,625
| +28% | +$977K | 1.16% | 25 |
|
|
2021
Q3 | $3.51M | Buy |
216,351
+36,400
| +20% | +$396K | 0.93% | 27 |
|
|
2021
Q2 | $1.14M | Buy |
179,951
+90,000
| +100% | +$581K | 0.24% | 69 |
|
|
2021
Q1 | $556K | Buy |
89,951
+21,000
| +30% | +$127K | 0.13% | 83 |
|
|
2020
Q4 | $476K | Sell |
68,951
-253,549
| -79% | -$1.62M | 0.14% | 68 |
|
|
2020
Q3 | $1.82M | Sell |
322,500
-35,000
| -10% | -$167K | 0.59% | 42 |
|
|
2020
Q2 | $1.82M | Buy |
+357,500
| New | +$1.49M | 0.53% | 41 |
|
|
2017
Q4 | – | Sell |
-50,000
| Closed | -$141K | – | 78 |
|
|
2017
Q3 | $141K | Buy |
+50,000
| New | +$135K | 0.09% | 67 |
|
|
2016
Q4 | – | Sell |
-46,600
| Closed | -$2.15M | – | 75 |
|
|
2016
Q3 | $2.15M | Buy |
+46,600
| New | +$2.63M | 1.5% | 24 |
|
DAFNA Capital Management's ISEE Position: Q3 2023 in Review
DAFNA Capital Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 612,975 shares — an estimated $24.1M sold.
DAFNA Capital Management first reported a position in ISEE in Q3 2016 and held it in 15 quarters. The position peaked at $24.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- DAFNA Capital Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- DAFNA Capital Management sold 612,975 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $24.1M.
- DAFNA Capital Management first reported a position in IVERIC bio, Inc. Common Stock in Q3 2016 and held it in 15 quarters.
- DAFNA Capital Management's IVERIC bio, Inc. Common Stock position peaked at $24.1M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.